Teva teams with Sinclair IS on cancer-pain med; Indian pharma grows 16.9%, no slowdown seen;

@FiercePharma: Judge tosses all but one claim in Fosamax patient suit against Merck. No punitive damages allowed. News | Follow @FiercePharma

> Teva Pharmaceutical Industries ($TEVA) is teaming up with Sinclair IS Pharma to promote the cancer-pain drug episil in 5 European markets beginning in the fourth quarter of this year. Story

> India's pharmaceutical industry has posted recent growth of 16.9%, Business Monitor International says, and there's little chance of a slowdown. Report

> Impax Labs ($IPXL) confirmed it's challenging Avanir Pharmaceuticals' patent on its Nuedexta drug for pseudobulbar affect. Impax release

> A long-term study of UCB's epilepsy drug Vimpat showed 'sustained reduction' in partial onset seizures for up to 8 years. UCB release

> Eisai and Abbott Laboratories ($ABT) have launched their pancreatic enzyme replacement drug Lipacreon in Japan. Article

> Insight Pharmaceuticals is taking over McNeil's North American portfolio of Monistat-branded antifungal products. News

> Baxter's BioPharma Solutions business wrapped up an expansion at a plant in Halle, Germany, where it turns out cytotoxic products for contract customers. Item

> Perrigo ($PRGO) won FDA approval for its version of the skin disease treatment Extina foam, which posts annual sales of $10 million. Report

Biotech News

@FierceBiotech: New R&D culture at GSK forces a challenging showdown. News | Follow @FierceBiotech

@JohnCFierce: Argonne has begun construction of an advanced protein crystallization lab for drug research. Report | Follow @JohnCFierce

@RyanMFierce: Virtual drug discovery MT @BioWorld: "We're trying to digitalize biotech," says Zymeworks CEO after $187M deal with Merck Item | Follow @RyanMFierce

@MaureenFierce: Can targeted drugs save Big Pharma? Article May help wean Big Pharma off of big blockbusters. | Follow @MaureenFierce

> Amgen backs $30M venture round for IBS-focused Ardelyx. Details

> Analyst: Benlysta's shortcomings offer blockbuster opening for new lupus drugs. More

> OrbiMed launches $600M fund for royalty, debt deals. Article

> E&Y: India's biotech industry hits the fast lane. Story

> Argonne preps $34.5M drug research lab to support protein projects. Report

Drug Delivery News

> FDA gives orphan OK to Pluristem's delivery platform for Buerger's disease. More

> Unilife aims prefilled syringes at patients who self inject. Story

> Newer drug-eluting stents reduce restenosis by 38%, thrombosis by half. Report

> MonoSol, KemPharm partner on second ADHD thin-film drug. Details

> QLT reports successes with eye drug delivery, analyst skeptical. Article

> A more precise method of making micelles. News

Medical Device News

> Cardiox raises $8M in Series C. Report

> Lantos aims to help military, consumers with 3D ear-mapping. News

> S&N takeover rumors rekindled. Story

> B. Braun, CareFusion in patent disputes. Details

> Medtronic, NuVasive clash over patents. More

> GI dynamics raises $85 in Australian IPO. Article

And Finally... Pregnant women who dip snuff have babies with more breathing problems than smoking women do. Story

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.